Posted inEuronext
GenSight Biologics secures cash, advances regulatory and manufacturing plans for LUMEVOQ
PARIS, FRANCE: GenSight Biologics, a biopharma company that develops gene therapies for eye and brain disorders, announced today that it has secured enough cash to operate until mid-February 2024, thanks…